Non-neuronal expression of components of the glutamatergic system has been increasingly observed, and our laboratory previously had demonstrated the etiological role of ectopically expressed metabotropic glutamate receptor 1 (Grm1/mGluR1) in mouse models of melanoma. We hypothesize that inappropriate glutamatergic signaling in other cell types can dysregulate growth leading to transformation and tumorigenesis. As most cancers are carcinomas, we selected an immortalized primary baby mouse kidney (iBMK) cell model to assess whether Grm1 can transform epithelial cells. These iBMK cells, engineered to be immortal yet nontumorigenic and retaining normal epithelial characteristics, were used as recipients for exogenous Grm1 cDNA. Several stable Grm1-expressing clones were isolated and the Grm1-receptors were shown to be functional, as evidenced by the accumulation of second messengers in response to Grm1 agonist. Additionally activated by agonist were mitogen-activated protein kinase (MAPK) and AKT/protein kinase B signaling cascades, the major intracellular pathways shown by many investigators to be critical in melanomagenesis and other neoplasms. These Grm1-iBMK cells exhibited enhanced cell proliferation in in vitro methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays and significant tumorigenicity in in vivo allografts. Persistent Grm1 expression was required for the maintenance of the in vivo tumorigenic phenotype as demonstrated by an inducible Grm1-silencing RNA. These are the first results that indicate that Grm1 can be an oncogene in epithelial cells. In addition, relevance to human disease in the corresponding tumor type of renal cell carcinoma (RCC) may be suggested by observed expression of GRM1/ mGluR1 in a number of RCC tumor biopsy samples and cell lines, and the effects of GRM1 modulation on tumorigenicity therein. Moreover, RCC cell lines exhibited elevated levels of extracellular glutamate, and some lines responded to drugs, which modulate the glutamatergic system. These findings imply a possible role for glutamate signaling apparatus in RCC cell growth, and that the glutamatergic system may be a therapeutic target in RCC.
INTRODUCTION
Although recognition of the glutamatergic system has been restricted to customary roles in the central nervous system (CNS) and linked neuropathologies, expression in a variety of tissues has come to be acknowledged. [1] [2] [3] [4] [5] [6] [7] [8] [9] Among such varied functions as in metabolism and structure, L-glutamate also is an evolutionarily conserved cell signaling molecule. 10 It thus becomes likely that dysfunction of the glutamatergic system can lead to diverse disease types in humans, including those of cell growth, or cancer.
In fact, our laboratory was first to implicate an aberrantly expressed metabotropic glutamate receptor 1 (Grm1/mGluR1) in the etiology of a neoplasm-melanoma-and subsequently demonstrated its significance in the progression of human malignancy. [11] [12] [13] Shin et al. 14 offered corroboration in a report that introduction of Grm1 into immortalized nontumorigenic mouse melanocytic cell lines can remove their requirement for TPA for in vitro growth, and render the cells tumorigenic in vivo. More recent work has developed a sound rationale for targeting this receptor for therapy in melanocytic disease. 15, 16 Recently, additional members of the metabotropic glutamate receptor (mGluR) family, Grm5 and GRM3, were shown to be important in melanoma pathogenesis. 17, 18 Results from these studies further associate glutamate signaling and melanoma.
Despite that melanocytes and neurons may have in common developmental origins from the embryonic neural crest, the intracellular signaling pathways accessible by these mGluR (metabotropic glutamate receptor) are distributed generally among diverse cell types. In experimental systems designed to study synaptic function, for example, it has been shown that ectopically expressed mGlus, including Grm1, can successfully link to endogenous signaling apparatus. 19 It is also noteworthy that concentrations of glutamate, the major excitatory neurotransmitter in the CNS and natural ligand for these receptors, can be orders of magnitude higher outside of the closely controlled microenvironment of the synapse, 20 and that activated mGlu receptors can couple indirectly to glutamate release, invoking an autocrine-like loop. 14, 21 In addition, various G protein-coupled receptors, including the glutamate receptors, may exhibit constitutive basal activity without the need for agonists.
We suggest that activity of an otherwise normal glutamate receptor in an ectopic cellular milieu can activate the signaling pathways, which dysregulate cell growth and ultimately lead to tumor formation. As most human cancers are of epithelial origin (carcinomas), we propose a model system to investigate whether Grm1 can transform epithelial cells. As part of a design to interrogate mechanisms of epithelial tumor progression, primary mouse epithelial cells underwent genetically defined immortalization that permitted the retention of normal epithelial characteristics, including a lack of innate tumorigenicity. 23, 24 The resulting W2 baby mouse kidney (immortalized primary baby mouse kidney (iBMK)) cells facilitate in vivo screening for elements that enable tumorigenesis, and cells of the sibling D3 line, additionally engineered for apoptosis impairment, allow for examination of factors that promote tumor growth.
In this report, we demonstrate that full-length wild-type Grm1 is tumorigenic when ectopically expressed in epithelial cells, and also couples to MAPK and AKT signaling, two of the hallmarkactivated signaling pathways fundamental to growth, proliferation and survival in cancer cells, including melanoma. In addition, a role for glutamate signaling apparatus in renal cell carcinoma (RCC) tumor cell growth is explored.
RESULTS
Stable expression of exogenous Grm1 in W2 and D3 iBMK epithelial cells Coding sequence for full-length form of the Grm1 receptor was subcloned into the standard mammalian expression vector pCIneo (Promega, Madison, WI, USA). This expression construct, or an empty-vector control, was transfected into W2 and D3 iBMK epithelial cells. Individual drug-resistant clones were isolated, expanded and screened by western immunoblot for Grm1 expression, which was detected at various levels in several stable Grm1 clones, but not in empty-vector controls or parental W2 and D3 cell lines (Figure 1a) . A number of Grm1-expressing and emptyvector control lines were selected for more detailed analysis.
Exogenous Grm1 receptor is functional in W2-and D3-Grm1 cells Accumulation of second messenger IP 3 in W2-and D3-Grm1 clones is specifically induced by Grm1 agonist. Guided by previous studies of G protein-coupled mGluR signaling, both in the CNS and in melanoma-derived tumor cells, 15, 25, 26 functionality of the exogenous receptor was assessed in W2-and D3-Grm1 clones by the accumulation of the phospholipase C second messenger inositol-1,4,5-triphosphate (IP 3 ) following challenge with Grm1 agonist. Results from a typical experiment for each cell type are shown (Figure 1b) . Although stimulation by the pharmacological agonist, L-quisqualic acid (Q), led to a significant increase in IP 3 levels over vehicle-only-treated W2-and D3-Grm1 cells, in all such clones, the increase examined in IP 3 was abrogated by preincubation of the cells with the Grm1-receptor-specific noncompetitive antagonist BAY 36-7620 (BAY). Fetal bovine serum (FBS), as a positive control for the system, led to an increase in IP 3 similar to that produced by the agonist Q (data not shown). Empty-vector transfectants (W2-and D3-vec) did not exhibit a Grm1-specific response. The IP 3 results are thus indicative of both the functionality and specificity of the exogenous Grm1-encoded cell-surface receptor introduced into the cells.
MAPK/extracellular signal-regulated kinase (ERK) is specifically activated by Grm1 agonist in both W2-and D3-Grm1 cells. Overactivation of the MAPK/ERK signaling pathways is a hallmark of many neoplasms, including melanoma. Phosphorylation of ERK 1/ 2 (MAPK3 and MAPK1), as assessed by immunoblot, was the read-out used to report the MAPK pathway activation by stimulation of exogenous Grm1 receptor. A maximal activation was seen within 5 min of induction by the agonist Q, followed by a slower diminution of signal. Typical results at the maximum are seen in Figures 2a and b. Once more, specificity of signaling was demonstrated by preincubation with the Grm1-receptor-specific antagonist BAY; under this condition, ERK/MAPK cannot be activated by Grm1 agonist.
AKT is specifically activated by Grm1 agonist in both W2-and D3-Grm1 cells. Recently, studies in our laboratory indicated that the Grm1 receptor could additionally signal to the AKT pathway in melanoma cells. 27 This pathway is known for roles in both mitogenic signaling and cell survival, and has increasingly become a focus in multiple malignancies. In experiments exactly parallel to those for ERK 1/2, AKT was also specifically stimulated or inhibited by Grm1 agonist or antagonist, respectively, again demonstrating a functioning receptor. A time-dependent activation in pAKT again paralleled that of phosphorylated ERK, with a slight lag, that is, a maximal stimulation closer to 10 min. A typical experiment is shown (Figure 2c ).
In vitro growth properties of W2-and D3-Grm1 cells W2-Grm1 clones uniformly exhibited an increased growth rate in vitro compared with W2-vec controls as measured by the standard MTT cell proliferation/viability assays. D3-Grm1 clones also displayed a consistent, but somewhat lesser increase in growth relative to D3-vec cells, as might be expected given that their D3 parental cells are already partially transformed/tumorigenic by engineered apoptosis defect (Supplementary Figure 1) . W2-and D3-Grm1 clones are tumorigenic in vivo We were, however, much more interested in the definitive measurement of neoplastic transformation: in vivo tumorigenicity. Several independent stable W2-Grm1 and D3-Grm1-iBMK clones were inoculated subcutaneously into the dorsal flanks of nude mice to establish allografts (n ¼ 20 each). As they developed, tumor dimensions were measured by vernier caliper twice weekly. Each study was terminated when tumor burden grew too great as per institutional guidelines. W2-Grm1 cells were permitted 13 weeks of growth after inoculation before termination. Depending on the independent W2-Grm1 clone in question, tumor volume averaged 4500-800 mm 3 . No measurable tumors whatsoever were observed from empty-vector-transfected W2-vec cells at this end point (Figure 3a ). D3-Grm1 tumors became palpable 1 week post injection. When D3-Grm1 line studies were ended after 8 weeks, tumors of D3-Grm1 clones had reached a mean size approaching 1400 mm 3 , whereas D3-vec cell tumors averaged only approximately one-fifth of that volume (Po0.001, analysis of variance) (Figure 3b ). Only excised W2-Grm1 and D3-Grm1 tumor samples expressed Grm1, as evaluated by immunoblots (Figures 3a and b) . Despite that parental D3 cells are already partially transformed/tumorigenic by engineered apoptosis defect, 28 Grm1-receptor expression most obviously enhanced in vivo tumorigenic growth potential. Figure 3 also illustrates Grm1-iBMK epithelial cell allograft-tumor growths, and the characteristic effects of tumor angiogenesis are overtly visible through skin as feeder blood vessels. As previously seen by Degenhardt et al., local invasion of iBMK allograft tumors was noted along with frequent angiogenesis and was classified as highly aggressive carcinoma. Representative high-magnification photomicrographs of hematoxylin and eosin (H&E)-stained formalin-fixed sections of tumors at termination of a study are also shown ( Figure 3 ).
Sustained expression of Grm1 is required to maintain W2-or D3-Grm1 tumorigenic phenotypes in vivo To determine whether sustained Grm1 expression is required to maintain the tumorigenic phenotypes, a doxycycline-inducible anti-Grm1 small interfering RNA (siRNA)-expression system was introduced into the W2-and D3-Grm1 clones. Anti-Grm1 and antigreen fluorescent protein (GFP)-control siRNA constructs, respectively, permitted assessing the effect of successful knockdown of Grm1, and the effect of an unrelated negative control (siRNA plasmid-containing GFP (siGFP)). Several independent Grm1 siRNA clones were isolated and evaluated first in vitro, by immunoblotting. siGrm1-but not siGFP-clones demonstrated consistent Figure 4a . Next, we assessed by allograft whether a reduction of Grm1 levels modulated tumorigenesis in vivo. Upon initial appearance of palpable tumors, mice were randomly segregated into two groups with equivalent tumor size (p10 mm 3 ), and doxycycline was thereafter included in the drinking water of the treated group (0.1% w/v). Each study was terminated after a set period or when tumor burden became excessive. Although there were no significant differences in allograft tumor growth observed between doxycycline-treated and -untreated W2-and D3-Grm1-siGFP (control siRNA) mice, there was sizeable inhibition of tumorigenesis in W2-(n ¼ 20, Po0.05, t-test) and D3-Grm1-siGrm1 (n ¼ 20, Po0.001, t-test) mice treated with doxycycline to induce siRNA knockdown of Grm1 (Figure 4b ).
GRM1 and the glutamatergic system in RCC Although originally designed only to substantiate the hypothesis that components of the glutamatergic system, such as mGluRs, can have a role in tumor cell growth, the clear results from our mouse kidney epithelial cell model system compelled us to undertake preliminary investigation of relevance to human disease in the corresponding tumor type of RCC. We determined to first extend the investigation with RCC cell lines. Figure 4a were treated with doxycycline (0.1% w/v in drinking water) to induce siRNA expression to knockdown levels of Grm1. Results indicated sustained expression of Grm1 is necessary to maintain W2-and D3-Grm1 tumor progression, respectively (Po0.05 and Po0.001, t-test, n ¼ 20). No significant differences in tumor growth were observed between doxycycline-treated and -untreated W2-and D3-Grm1-siGFP (control siRNA) mice.
RCC cell lines express GRM1. Total RNA was isolated from a panel of four standard RCC cell lines, UOK115, UOK117, UOK121 and UOK122, originally established from resected stage IV disease tumors. 29 Results from initial reverse transcription PCR performed using gene-specific primers demonstrated GRM1 transcripts in these RCC cell lines, but not in HEK293, a human embryonic kidney cell line used as control (Supplementary Figure 2) . Fittingly, HEK293 commonly is used as a recipient for exogenous mGluRs to study individual mGlu function away from the synaptic environment. [30] [31] [32] Expression was also seen in the RCC cell lines at the protein level, but not in HEK293 cells ( Figure 5 ). Included as controls in the immunoblot were GRM1-negative p'mel* immortalized human melanocytes, 33 as well as a stable GRM1 þ p'mel* clone transfected with exogenous human GRM1 cDNA, and the GRM1 þ human metastatic melanoma C8161 þ cell line. 34 RCC cell lines release glutamate. We measured the levels of extracellular glutamate in these RCC cell lines, as varied studies, including ours with melanoma, have suggested that G proteincoupled receptors with oncogenic activity frequently display locally enhanced levels of ligand produced and released by tumor cells (autocrine) or surrounding cells (paracrine). 35, 36 These measurements were done in parallel with MTT cell proliferation/ viability assays to be sure any increases in extracellular glutamate were not due to release by cell death (Figure 6a) . Each of the RCC lines showed several-fold excess in levels of extracellular glutamate compared with control HEK293 cells (for example, under these conditions, UOK117 a maximum upwards of 300 mM glutamate, and HEK293 never 41/10 of that). Even when adjusted for differences in growth rate over the course of the experiment as measured by MTT, the contrast between the RCC cells and HEK293 remained striking (Figure 6b ).
RCC cells respond to the anti-glutamatergic drug riluzole. Originally approved by the Food and Drug Administration as a neuroprotective agent known to inhibit glutamate release, riluzole previously was shown by our group to reduce the growth of melanoma tumor cells that release elevated levels of extracellular glutamate. 14, 15 Analyses were performed on RCC cells treated with this anti-glutamatergic drug at a working concentration guided by pilot experiments and previous studies in melanoma. 14, 15 First, MTT cell proliferation/viability assays demonstrated two RCC lines were growth-inhibited by riluzole beyond the response of control HEK293 cells to the drug. UOK115 by about 20% and UOK117 by about 50%, after treatment for 96 h at 25 mM ( Figure 7) . Next, cellcycle analyses were performed on RCC cells treated with riluzole at the same concentration, for the indicated time periods. Population distributions of HEK293 cells were not affected by riluzole at this (a) Anti-GRM1 siRNA constructs introduced into UOK117 RCC cells permitted doxycycline-inducible knockdown of endogenous GRM1 at the protein level as assessed by immunoblots. GRM1 þ control is IMR32 cell extract. Levels of GRM1 expression in three independent siGRM1-UOK117 clones as percentage of control day 0 by densitometry. (b) In vivo reduction of tumor progression by anti-GRM1 siRNA. Mice bearing xenografted tumors developing from two independent clones of siGRM1-UOK117 RCC cells chosen from a were treated with doxycycline to induce siRNA knockdown of endogenous GRM1 levels. Results implied that sustained expression of GRM1 is in part necessary to maintain UOK117 tumor progression (both clones Po0.001, t-test, n ¼ 20).
riluzole with either the apparent cytostatic (UOK115) or cytotoxic/ apoptotic (UOK117) effect of the drug, each typically seen in our lab for different human melanoma cell lines. 14, 15 Sustained expression of GRM1 is required to maintain UOK117 RCC tumorigenic phenotype in vivo. To examine whether interference in the expression of GRM1 in RCC cells would affect their tumorigenic phenotype in vivo, an anti-GRM1 siRNA-expression system was introduced into UOK117 RCC cells, in an experimental protocol exactly paralleling that of engineered iBMK-Grm1 clones described above. An evaluation of doxycycline-induced silencing in three of the independently isolated GRM1 siRNA lines is shown by immunoblotting in Figure 9a . From these, clones 2 and 4 were selected for xenograft. At the termination of the in vivo studies, a marked inhibition of tumor progression was noted (Figure 9b ) in doxycycline-treated mice (both clones n ¼ 20, Po0.001, t-test). Results thus implied that sustained expression of GRM1 is at least in part necessary to maintain UOK117 tumor progression in vivo.
RCC tumor tissues express GRM1. Although both the available anti-human GRM1 antibodies and the inherent heterogeneity and variability of tissues obtained during surgical procedures can be problematic, the results from cultured RCC cells compelled us, for completeness, to perform initial experiments to assess GRM1 expression in tumor tissue. A small collection of six pairs of anonymized tumor and adjacent 'normal' biopsy-tissue sections from patients with RCC was obtained through the Tissue Retrieval Service at the Cancer Institute of New Jersey and analyzed for GRM1 protein by immunohistochemistry (IHC). Initial results, both visual by photomicroscopy, and unbiased quantitative assessment of IHC staining of digitized slides using an Aperio ScanScopeGL system (v 10.1.3.2028, Aperio Technologies Inc., Vista, CA, USA) with Aperio ImageScope software (Aperio) indicated that GRM1 is expressed in at least a subset of these tissues. It is readily apparent in a representation (Figure 10a ) of the automated quantification that in these samples, there was on average a greater number of GRM1 þ cells in those tissues that had been designated tumor than those termed adjacent normal. Interestingly, in some slides, the IHC revealed visually provocative patterning of GRM1 þ -stained cells, displaying classic crab-like invasion into an area of unstained cells, or in others, characteristic tumor-like cellular disorganization (Figure 10b ). 
DISCUSSION
Previously, our laboratory reported a line of transgenic mice (TG-3), which displays spontaneous melanoma with 100% penetrance due to insertional mutagenesis causing a constitutive mis-expression of Grm1 in its melanocytes. 11, 13 The significance of Grm1 (mGluR1) receptors in the progression of human melanoma was subsequently demonstrated. 11, 15 It was established that in TG-3 tumor-derived cells, like in the CNS, Grm1 signaling coupled through a G protein to phospholipase C and its second messengers IP 3 and diacylglycerol 26 -part of a signaling apparatus available to many mammalian cell types. Although melanoma is one of the most deadly cancers, carcinomas are by far the most common. We thus set out to assess whether Grm1 is able to transform epithelial cells.
We hypothesized that activity of an otherwise normal glutamate receptor in an ectopic cellular milieu can activate the signaling pathways which dysregulate cell growth and ultimately lead to tumor formation in epithelial cells. Indeed, functional expression of Grm1 in normal W2 baby mouse kidney epithelial cells enabled a tumorigenic potential as evidenced in allograft assays, whereas empty-vector-transfected W2-vec cell inoculations remained tumor-free in vivo. Although D3 cells already have been partially transformed by engineered apoptosis defect and are tumorigenic, 24 it is readily apparent from our results that expression of functional Grm1 receptor significantly enhanced and accelerated the tumorigenic potential of D3 cells relative to multiple empty-vector control lines in vivo. Inducible silencing RNA against Grm1 was used to demonstrate that sustained expression of Grm1 is required to maintain W2-or D3-Grm1 tumorigenic phenotypes. It additionally was shown that in both W2-and D3-Grm1 epithelial cells, the exogenous receptor specifically activated the endogenous MAPK and AKT signaling pathways when stimulated by Grm1 agonist.
It is an attractive concept that signaling from a single cellsurface mGluR can activate at least two of the hallmark-activated signaling pathways thought to have essential roles in growth, survival, invasion, and even angiogenesis and in human tumors, MAPK and AKT. [37] [38] [39] [40] [41] It may be argued that the human tumor type corresponding to that of our experimental mouse model system is kidney cancer, a neoplasm newly affecting over 65 000 persons and responsible for more than 13 000 deaths in the United States this year. 42 The incidence of this neoplasm has been steadily increasing worldwide for decades. [43] [44] [45] By far the most common type, RCC is thought to originate in the lining of the proximal convoluted tubule. Interestingly, RCC is one of the coexistent or subsequent primary neoplasms that have been reported in statistically significant higher incidence in patients diagnosed with melanoma. 46, 47 Our initial studies demonstrated GRM1 expression in tested subsets of RCC cell lines and tumors, and indicated a susceptibility of RCC cells to drugs, which modulate the glutamatergic system. Further investigation into the necessity for sustained expression of GRM1 in human RCC cells implied that, at least in a subset of cases, it may be one of the requirements for maintenance of the tumorigenic phenotype in vivo. These findings suggest a possible role for glutamate signaling apparatus in RCC cell growth and maintenance.
Much early effort researching the glutamatergic system was restricted to the CNS. mGluRs, originally thought to be confined to neural cells, may have more diverse physiological functions as they have been found to be expressed in a range of non-neuronal tissues in recent years. After Grm1/mGluR1 first was linked to melanomagenesis by Chen et al., various mGlus subsequently have been implicated in human melanoma and an increasing subset of human malignancies. 17, 18, 48 The mGluRs are highly druggable G protein-coupled receptors. 49 For example, appropriate pharmacological modulation of mGlu2/3 and mGlu4, respectively, inhibited the growth of human glioma cells in culture 50 and medulloblastomas in xenografts. 51 It may thus be suggested that modulation of the glutamatergic system can offer therapeutic benefits in non-neuronal neoplasms as well. Significant investigation over the past few years has gone into design and testing of therapeutics to modulate the glutamatergic system to address a diversity of neurological and neuropsychiatric disorders, [52] [53] [54] and it may be possible to leverage these studies in the quest for anticancer therapeutics. Riluzole, the anti-glutamatergic drug used in this study, is the only US Food and Drug Administration approved treatment for the neurodegenerative disease amyotrophic lateral sclerosis. 55, 56 Recent work by Chen and Goydos groups indicated that riluzole reduced melanoma-cell glutamate release, resulted in cell-cycle arrest and subsequent apoptosis in vitro, and impeded xenografted melanoma tumor growth in vivo. 15, 57, 58 These preclinical results led to an exploratory phase 0 clinical trial of oral riluzole in patients with advanced melanoma. Pre-and post-treatment tumor biopsies and positron emission tomography (PET) scans were performed to monitor cellular response and tumor metabolic activity. Assessment of proliferation and apoptotic markers revealed that four of eleven patients who completed the protocol had pronounced responses to riluzole administration as shown by increased apoptosis and tumor shrinkage. 16 The completion of a more significant phase II clinical trial of the drug for anti-melanoma therapy is expected presently.
In addition to having been observed in a subset of aggressive melanoma cell lines as compared with normal melanocytes and where so far linked with GRM1 expression, 14, 15 amplified release of extracellular glutamate has been noted in malignant gliomas, 59 in cell lines of varied tumor types in bone metastases 60, 61 and more recently in triple-negative breast cancer cells, 62 again implying correlation of the glutamatergic system with malignant potential. Current interest in the distinctive metabolic changes in cancer cells and their relationships with signaling networks and proliferation includes investigations of glutamate both as a cellular messenger and as a metabolic support, particularly as a product of glutaminase in glutaminolysis. 63 Given our own published and unpublished observations, and examples such as in bone metastasis 61 and breast cancer, 62 it is thus somewhat encouraging for prospective therapeutic benefit that the glutamate transport system in cancer cells can be modulated pharmacologically.
Taken together, the results presented in this report establish that Grm1 indeed can be oncogenic in epithelial cells and can activate the multiple characteristic cancer-signaling pathwaysand that components of the glutamatergic system are active in RCC. Although beyond the scope of the current work, our preliminary observations offer a rationale for both comprehensive survey of expression of GRM1 and other mGluRs, which are highly druggable G protein-coupled receptors, and systematic examination of other elements of glutamate signaling, as possible novel targets for RCC therapy.
MATERIALS AND METHODS
Cell lines, culture conditions and DNA transfection DMEM and RPMI were supplemented with 100 U/ml-100 mg/ml penicillinstreptomycin (Invitrogen, Carlsbad, CA, USA). Incubators were maintained at 37 1C and 5% CO 2 . For signaling studies and glutamate assays, exogenous glutamate was minimized by use of glutamate and glutamine-free medium supplemented with GlutaMax at 2 mM, (Invitrogen), with or without dialyzed FBS. 15, 26 The derivation of W2 and D3 baby mouse kidney epithelial cell lines has been described. 28 W2 and D3 were cultured in DMEM supplemented with 5% FBS. All DNA transfections were performed with Lipofectamine 2000 according to the manufacturer (Invitrogen). Coding sequence for the full-length form of the receptor was subcloned from mouse-brain Grm1 cDNA 14, 64 into mammalian expression vector pCI-neo (Promega). Stable Grm1-or empty-vectortransfected clones were selected in 1 (W2) or 2 mg/ml (D3) Geneticin Grm1 is an oncogene in epithelial cells JJ Martino et al (Invitrogen). siGrm1 or siGFP sequence 14 was cloned into the inducible siRNA expression vector pRNATin-H1.2/Hygro (GenScript, Piscataway, NJ, USA) and cotransfected with TetR plasmid. 65 Stable siRNA/TetR-transfected clones were selected in Hygromycin-B (Invitrogen) at a concentration determined for each line (200-240 mg/ml). RCC cell lines UOK115, UOK117, UOK121 and UOK122 29 were routinely grown in DMEM with 10% FBS. siGRM1-66 UOK117 clones were selected in 300 mg/ml Geneticin and 25-40 mg/ml Hygromycin-B.
Inositol-1,4,5-triphosphate measurement IP 3 measurement was a modification of Thandi et al., 67 performed as described previously. 26 Briefly, sequential changes of medium-starved cells of stimulatory factors, glutamate and other cell-surface receptor ligands to minimize signaling, and also replaced the intracellular pool of inositol with radiolabeled precursor to render IP 3 production measurable.
Antibodies and western immunoblotting
Anti-total-ERK 1/2, phospho-ERK 1/2, total-AKT and phospho-AKT were obtained from Cell Signaling Technology (Danvers, MA, USA); anti-Grm1/ mGluR1 from BD Biosciences (San Jose, CA, USA); anti-GRM1/mGluR1 from Upstate/Millipore (Billerica, MA, USA); and anti-a-tubulin from Sigma (St Louis, MO, USA). Cells and tissue extracts were prepared in NP40-containing buffer with protease and phosphatase inhibitors as described previously; 68 protein concentrations were determined with Detergent Compatible Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were resolved by Tris-Glycine polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane by wet tank electroblotting. After overnight incubation with primary antibodies, blots were visualized with Amersham ECL-HRP Linked Secondary Antibodies and ECL Plus Western Blotting Detection Reagents (GE Healthcare Life Sciences, Piscataway, NJ, USA). Densitometry by OptiQuant software (PerkinElmer, Shelton, CT, USA).
Immunohistochemistry
The Tissue Analytical Services at the Cancer Institute of New Jersey performed the standard IHC for GRM1, and unbiased quantitative assessment of IHC staining was completed using a digital Aperio ScanScopeGL system and ImageScope software (v 10.1.3.2028) (Aperio Technologies Inc., Vista, CA, USA) according to the manufacturer's protocol with modifications as described. 69 Cell proliferation/viability (MTT) assay Cells were typically seeded at 1-2 Â 10 3 cells per well in a 96-well culture plate. At designated time points, 0.1 volumes of 5 mg/ml Thiazolyl Blue Tetrazolium Bromide (Sigma) in 1 Â phosphate-buffered saline were added to growth medium, incubated for 4 h at 37 1C and then solubilized overnight at 37 1C with an equal volume of 10% sodium dodecyl sulfate/ 0.1 M HCl. A 96-well plate reader (Infinite 200 Tecan USA, Durham, NC, USA) was used to measure absorbance at 550 nm with a reference wavelength of 750 nm.
In vivo tumor-growth assay
The animal protocols were approved by the Institutional Review Board for the Use and Care of Animals and the Animal Care and Facilities Committee of Rutgers University. Expanded from independent clones, 10 6 cells were resuspended in 0.1 ml sterile phosphate-buffered saline and injected subcutaneously into the dorsal flanks of nude mice (Taconic, Hudson, NY, USA) to establish allografts or xenografts. Tumors were measured with a vernier caliper twice weekly, and tumor volume was calculated as V ¼ d2 Â D/2. 70 Studies were terminated as soon as tumor volumes reached maximally permissible size.
Glutamate release assay
Glutamate concentration in culture medium 'conditioned' by tumor cells was measured by enzyme-based colorimetric assay in a microplate reader at 450 nm as per the manufacturer (Glutamate Assay Kit; Biovision, Mountain View, CA, USA). Cells were generally seeded at 1-2 Â 10 3 per well and cultured in 200 ml glutamate/glutamine-free medium as described above, with 10% dialyzed FBS. At measurement, half of the volume was removed from each well for glutamate assay, and cell-viability immediately assessed by MTT assay.
Cell-cycle analysis Cells were plated at 5 Â 10 5 -1 Â 10 6 per 100-mm dish and treated with 25 mM riluzole, vehicle (dimethyl sulfoxide) or left untreated for 24-72 h as specified. Adherent and floating cells were pooled, pelleted, washed twice with ice-cold 1 Â phosphate-buffered saline, fixed by drop-wise addition of ice-cold 70% ethanol while mixing and stored at À 20 1C. Fixed cells were washed twice with and resuspended in 1 Â phosphate-buffered saline, treated with RNase A solution (Sigma) at 100 mg/ml and stained with propidium iodide (Sigma) at 10 mg/ml for 30 min. Cell-cycle analysis was performed on a Coulter Cytomics FC500 Flow Cytometer (Beckman Coulter, Fullerton, CA, USA) at the Analytical Cytometry Core Facility, Rutgers University.
